Our Company
Products
- Tedopi®
- OSE-279
- OSE-127/Lusvertikimab
- FR104/VEL-101
- BI 765063
- BI 770371
- OSE-230
- CLEC-1
- BiCKI®
Research & Development
- Scientific publications
Investors
Partnerships
News
- Agenda
- Press Releases
Contact

en

fr

Retour aux communiqués

Date

OSE Immunotherapeutics Announces Participation In Upcoming Investor Conferences

Head Office

22, boulevard Benoni Goulin
44200 Nantes – France

Tel : +33 (0)2 28 29 10 10

Email : contact@ose-immuno.com

Paris Office

10, place de Catalogne
75014 Paris – France

Tel : +33 (0)1 43 29 78 57

Fax : +33 (0)1 42 03 04 16

Our Company

Products

Investors

Agenda

Research & Development

Partnerships

Follow us

©2021 ose-immuno

Financial documents

Legal information and Personal data protection policy

Site internet créé par Adveris